Global Sarcoma Therapeutics Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	143 Pages	TechNavio	June, 2024	INF19006961

Best Price Guarantee
Price	from $2,500
Length	143 Pages
Publisher	TechNavio
Published Date	June, 2024
SKU	INF19006961

Global Sarcoma Therapeutics Market 2024-2028

The sarcoma therapeutics market is forecasted to grow by USD 1110.8 mn during 2023-2028, accelerating at a CAGR of 8.51% during the forecast period. The report on the sarcoma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by patient assistance programs, increasing strategic alliances, and launch of novel drugs.

Technavio's sarcoma therapeutics market is segmented as below:

By Type

Soft tissue sarcoma
Osteosarcoma

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the r and d of new drugs for oh treatment as one of the prime reasons driving the sarcoma therapeutics market growth during the next few years. Also, financial assistance programs and reimbursements schemes and advent of regenerative medicine will lead to sizable demand in the market.

The report on the sarcoma therapeutics market covers the following areas:

Sarcoma therapeutics market sizing
Sarcoma therapeutics market forecast
Sarcoma therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading sarcoma therapeutics market vendors that include Adaptimmune Therapeutics plc, Advenchen Laboratories LLC, Agenus Inc., Agios Inc., Athenex Inc., Bayer AG, Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Ipsen Pharma, Johnson and Johnson Services Inc., Karyopharm Therapeutics Inc., LadRx Corp., Mirati Therapeutics Inc., Novartis AG, Pfizer Inc., PharmaMar SA, and SillaJen Co. Ltd.. Also, the sarcoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market by Geography; Executive Summary - Chart on Market Segmentation by Type; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 2.2 Market characteristics; Market characteristics analysis; 2.3 Value chain analysis; Value Chain Analysis
3 Market Sizing: 3.1 Market definition; Offerings of companies included in the market definition; 3.2 Market segment analysis; Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Chart on Global - Market size and forecast 2023-2028 ($ million); Data Table on Global - Market size and forecast 2023-2028 ($ million); Chart on Global Market: Year-over-year growth 2023-2028 (%); Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global Sarcoma Therapeutics Market 2018 - 2022; Historic Market Size - Data Table on Global Sarcoma Therapeutics Market 2018 - 2022 ($ million); 4.2 Type segment analysis 2018 - 2022; Historic Market Size - Type Segment 2018 - 2022 ($ million); 4.3 Geography segment analysis 2018 - 2022; Historic Market Size - Geography Segment 2018 - 2022 ($ million); 4.4 Country segment analysis 2018 - 2022; Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type: 6.1 Market segments; Chart on Type - Market share 2023-2028 (%); Data Table on Type - Market share 2023-2028 (%); 6.2 Comparison by Type; Chart on Comparison by Type; Data Table on Comparison by Type; 6.3 Soft tissue sarcoma - Market size and forecast 2023-2028; Chart on Soft tissue sarcoma - Market size and forecast 2023-2028 ($ million); Data Table on Soft tissue sarcoma - Market size and forecast 2023-2028 ($ million); Chart on Soft tissue sarcoma - Year-over-year growth 2023-2028 (%); Data Table on Soft tissue sarcoma - Year-over-year growth 2023-2028 (%); 6.4 Osteosarcoma - Market size and forecast 2023-2028; Chart on Osteosarcoma - Market size and forecast 2023-2028 ($ million); Data Table on Osteosarcoma - Market size and forecast 2023-2028 ($ million); Chart on Osteosarcoma - Year-over-year growth 2023-2028 (%); Data Table on Osteosarcoma - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Type; Market opportunity by Type ($ million); Data Table on Market opportunity by Type ($ million)
7 Customer Landscape: 7.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
8 Geographic Landscape: 8.1 Geographic segmentation; Chart on Market share by geography 2023-2028 (%); Data Table on Market share by geography 2023-2028 (%); 8.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 8.3 North America - Market size and forecast 2023-2028; Chart on North America - Market size and forecast 2023-2028 ($ million); Data Table on North America - Market size and forecast 2023-2028 ($ million); Chart on North America - Year-over-year growth 2023-2028 (%); Data Table on North America - Year-over-year growth 2023-2028 (%); 8.4 Europe - Market size and forecast 2023-2028; Chart on Europe - Market size and forecast 2023-2028 ($ million); Data Table on Europe - Market size and forecast 2023-2028 ($ million); Chart on Europe - Year-over-year growth 2023-2028 (%); Data Table on Europe - Year-over-year growth 2023-2028 (%); 8.5 Asia - Market size and forecast 2023-2028; Chart on Asia - Market size and forecast 2023-2028 ($ million); Data Table on Asia - Market size and forecast 2023-2028 ($ million); Chart on Asia - Year-over-year growth 2023-2028 (%); Data Table on Asia - Year-over-year growth 2023-2028 (%); 8.6 Rest of World (ROW) - Market size and forecast 2023-2028; Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 8.7 US - Market size and forecast 2023-2028; Chart on US - Market size and forecast 2023-2028 ($ million); Data Table on US - Market size and forecast 2023-2028 ($ million); Chart on US - Year-over-year growth 2023-2028 (%); Data Table on US - Year-over-year growth 2023-2028 (%); 8.8 China - Market size and forecast 2023-2028; Chart on China - Market size and forecast 2023-2028 ($ million); Data Table on China - Market size and forecast 2023-2028 ($ million); Chart on China - Year-over-year growth 2023-2028 (%); Data Table on China - Year-over-year growth 2023-2028 (%); 8.9 Germany - Market size and forecast 2023-2028; Chart on Germany - Market size and forecast 2023-2028 ($ million); Data Table on Germany - Market size and forecast 2023-2028 ($ million); Chart on Germany - Year-over-year growth 2023-2028 (%); Data Table on Germany - Year-over-year growth 2023-2028 (%); 8.10 Canada - Market size and forecast 2023-2028; Chart on Canada - Market size and forecast 2023-2028 ($ million); Data Table on Canada - Market size and forecast 2023-2028 ($ million); Chart on Canada - Year-over-year growth 2023-2028 (%); Data Table on Canada - Year-over-year growth 2023-2028 (%); 8.11 UK - Market size and forecast 2023-2028; Chart on UK - Market size and forecast 2023-2028 ($ million); Data Table on UK - Market size and forecast 2023-2028 ($ million); Chart on UK - Year-over-year growth 2023-2028 (%); Data Table on UK - Year-over-year growth 2023-2028 (%); 8.12 Market opportunity by geography; Market opportunity by geography ($ million); Data Tables on Market opportunity by geography ($ million)
9 Drivers, Challenges, and Opportunity/Restraints: 9.1 Market drivers; 9.2 Market challenges; 9.3 Impact of drivers and challenges; Impact of drivers and challenges in 2023 and 2028; 9.4 Market opportunities/restraints
10 Competitive Landscape: 10.1 Overview; 10.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 10.3 Landscape disruption; Overview on factors of disruption; 10.4 Industry risks; Impact of key risks on business
11 Competitive Analysis: 11.1 Companies profiled; Companies covered; 11.2 Market positioning of companies; Matrix on companies position and classification; 11.3 Agios Inc.; Agios Inc. - Overview; Agios Inc. - Product / Service; Agios Inc. - Key offerings; 11.4 Athenex Inc.; Athenex Inc. - Overview; Athenex Inc. - Product / Service; Athenex Inc. - Key offerings; 11.5 Bayer AG; Bayer AG - Overview; Bayer AG - Business segments; Bayer AG - Key news; Bayer AG - Key offerings; Bayer AG - Segment focus; 11.6 Eisai Co. Ltd.; Eisai Co. Ltd. - Overview; Eisai Co. Ltd. - Business segments; Eisai Co. Ltd. - Key offerings; Eisai Co. Ltd. - Segment focus; 11.7 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; 11.8 Ipsen Pharma; Ipsen Pharma - Overview; Ipsen Pharma - Business segments; Ipsen Pharma - Key offerings; Ipsen Pharma - Segment focus; 11.9 Johnson and Johnson Services Inc.; Johnson and Johnson Services Inc. - Overview; Johnson and Johnson Services Inc. - Business segments; Johnson and Johnson Services Inc. - Key news; Johnson and Johnson Services Inc. - Key offerings; Johnson and Johnson Services Inc. - Segment focus; 11.10 Karyopharm Therapeutics Inc.; Karyopharm Therapeutics Inc. - Overview; Karyopharm Therapeutics Inc. - Product / Service; Karyopharm Therapeutics Inc. - Key offerings; 11.11 Novartis AG; Novartis AG - Overview; Novartis AG - Business segments; Novartis AG - Key news; Novartis AG - Key offerings; Novartis AG - Segment focus; 11.12 PharmaMar SA; PharmaMar SA - Overview; PharmaMar SA - Business segments; PharmaMar SA - Key offerings; PharmaMar SA - Segment focus
12 Appendix: 12.1 Scope of the report; 12.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 12.3 Currency conversion rates for US$; Currency conversion rates for US$; 12.4 Research methodology; Research methodology; 12.5 Data procurement; Information sources; 12.6 Data validation; Data validation; 12.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 12.8 Data synthesis; Data synthesis; 12.9 360 degree market analysis; 360 degree market analysis; 12.10 List of abbreviations; List of abbreviations

Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market by Geography; Exhibits5: Executive Summary - Chart on Market Segmentation by Type; Exhibits6: Executive Summary - Chart on Incremental Growth; Exhibits7: Executive Summary - Data Table on Incremental Growth; Exhibits8: Executive Summary - Chart on Company Market Positioning; Exhibits9: Parent Market; Exhibits10: Data Table on - Parent Market; Exhibits11: Market characteristics analysis; Exhibits12: Value Chain Analysis; Exhibits13: Offerings of companies included in the market definition; Exhibits14: Market segments; Exhibits15: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibits16: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibits17: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits18: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits19: Historic Market Size - Data Table on Global Sarcoma Therapeutics Market 2018 - 2022 ($ million); Exhibits20: Historic Market Size - Type Segment 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million); Exhibits23: Five forces analysis - Comparison between 2023 and 2028; Exhibits24: Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits29: Chart on Market condition - Five forces 2023 and 2028; Exhibits30: Chart on Type - Market share 2023-2028 (%); Exhibits31: Data Table on Type - Market share 2023-2028 (%); Exhibits32: Chart on Comparison by Type; Exhibits33: Data Table on Comparison by Type; Exhibits34: Chart on Soft tissue sarcoma - Market size and forecast 2023-2028 ($ million); Exhibits35: Data Table on Soft tissue sarcoma - Market size and forecast 2023-2028 ($ million); Exhibits36: Chart on Soft tissue sarcoma - Year-over-year growth 2023-2028 (%); Exhibits37: Data Table on Soft tissue sarcoma - Year-over-year growth 2023-2028 (%); Exhibits38: Chart on Osteosarcoma - Market size and forecast 2023-2028 ($ million); Exhibits39: Data Table on Osteosarcoma - Market size and forecast 2023-2028 ($ million); Exhibits40: Chart on Osteosarcoma - Year-over-year growth 2023-2028 (%); Exhibits41: Data Table on Osteosarcoma - Year-over-year growth 2023-2028 (%); Exhibits42: Market opportunity by Type ($ million); Exhibits43: Data Table on Market opportunity by Type ($ million); Exhibits44: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits45: Chart on Market share by geography 2023-2028 (%); Exhibits46: Data Table on Market share by geography 2023-2028 (%); Exhibits47: Chart on Geographic comparison; Exhibits48: Data Table on Geographic comparison; Exhibits49: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibits50: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibits51: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits52: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits53: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibits54: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibits55: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits56: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits57: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibits58: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibits59: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits60: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits61: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits62: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits63: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits64: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits65: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits66: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits67: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits68: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits69: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibits70: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibits71: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits72: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits73: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibits74: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibits75: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits76: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits77: Chart on Canada - Market size and forecast 2023-2028 ($ million); Exhibits78: Data Table on Canada - Market size and forecast 2023-2028 ($ million); Exhibits79: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits80: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits81: Chart on UK - Market size and forecast 2023-2028 ($ million); Exhibits82: Data Table on UK - Market size and forecast 2023-2028 ($ million); Exhibits83: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits84: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits85: Market opportunity by geography ($ million); Exhibits86: Data Tables on Market opportunity by geography ($ million); Exhibits87: Impact of drivers and challenges in 2023 and 2028; Exhibits88: Overview on criticality of inputs and factors of differentiation; Exhibits89: Overview on factors of disruption; Exhibits90: Impact of key risks on business; Exhibits91: Companies covered; Exhibits92: Matrix on companies position and classification; Exhibits93: Agios Inc. - Overview; Exhibits94: Agios Inc. - Product / Service; Exhibits95: Agios Inc. - Key offerings; Exhibits96: Athenex Inc. - Overview; Exhibits97: Athenex Inc. - Product / Service; Exhibits98: Athenex Inc. - Key offerings; Exhibits99: Bayer AG - Overview; Exhibits100: Bayer AG - Business segments; Exhibits101: Bayer AG - Key news; Exhibits102: Bayer AG - Key offerings; Exhibits103: Bayer AG - Segment focus; Exhibits104: Eisai Co. Ltd. - Overview; Exhibits105: Eisai Co. Ltd. - Business segments; Exhibits106: Eisai Co. Ltd. - Key offerings; Exhibits107: Eisai Co. Ltd. - Segment focus; Exhibits108: GlaxoSmithKline Plc - Overview; Exhibits109: GlaxoSmithKline Plc - Business segments; Exhibits110: GlaxoSmithKline Plc - Key news; Exhibits111: GlaxoSmithKline Plc - Key offerings; Exhibits112: GlaxoSmithKline Plc - Segment focus; Exhibits113: Ipsen Pharma - Overview; Exhibits114: Ipsen Pharma - Business segments; Exhibits115: Ipsen Pharma - Key offerings; Exhibits116: Ipsen Pharma - Segment focus; Exhibits117: Johnson and Johnson Services Inc. - Overview; Exhibits118: Johnson and Johnson Services Inc. - Business segments; Exhibits119: Johnson and Johnson Services Inc. - Key news; Exhibits120: Johnson and Johnson Services Inc. - Key offerings; Exhibits121: Johnson and Johnson Services Inc. - Segment focus; Exhibits122: Karyopharm Therapeutics Inc. - Overview; Exhibits123: Karyopharm Therapeutics Inc. - Product / Service; Exhibits124: Karyopharm Therapeutics Inc. - Key offerings; Exhibits125: Novartis AG - Overview; Exhibits126: Novartis AG - Business segments; Exhibits127: Novartis AG - Key news; Exhibits128: Novartis AG - Key offerings; Exhibits129: Novartis AG - Segment focus; Exhibits130: PharmaMar SA - Overview; Exhibits131: PharmaMar SA - Business segments; Exhibits132: PharmaMar SA - Key offerings; Exhibits133: PharmaMar SA - Segment focus; Exhibits134: Inclusions checklist; Exhibits135: Exclusions checklist; Exhibits136: Currency conversion rates for US$; Exhibits137: Research methodology; Exhibits138: Information sources; Exhibits139: Data validation; Exhibits140: Validation techniques employed for market sizing; Exhibits141: Data synthesis; Exhibits142: 360 degree market analysis; Exhibits143: List of abbreviations